Skip to content

Evaluation of the efficacy and safety of Nd:YAG picosecond laser and intense pulsed light in facial skin whitening: A split-face randomized controlled clinical study

Evaluation of the efficacy and safety of Nd:YAG picosecond laser and intense pulsed light in facial skin whitening: A split-face randomized controlled clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098833
Enrollment
Unknown
Registered
2025-03-13
Start date
2025-03-13
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin whitening

Interventions

Test side:The treatment equipment was PicoWell Pro picosecond Nd:YAG laser therapy instrument (Peninsula Medical, China) with wavelength of 1064 nm, pulse width of 250 ps, spot size of 8 ~ 10 mm, freq
Control side:The treatment equipment was M22 intense pulsed light (Lumenis Limited, USA), filter 560 nm (type III), 590 nm (type IV-V), spot size 15 mm×35 mm, double pulse, pulse width 3.0 ~ 5.0 ms, e

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 to 60 years old, gender unrestricted, those who require facial skin whitening; 2.Fitzpatrick skin types III to V; 3.Voluntary participation and signing of the informed consent form. 4.Good compliance and willingness to cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with facial inflammation, infection, ulceration or other skin diseases, including chloasma, nevus fusco-coccineus, seborrheic keratosis, etc. 2. Patients who have undergone laser, radiofrequency, chemical peeling, botulinum toxin injection, etc. within the past six months. 3. Patients who have been exposed to intense sunlight or undergone sunbathing within the past month. 4. Patients who are photosensitive or are currently using photosensitive drugs (oral or topical). 5. Patients with systemic diseases, immune deficiency diseases or using immunosuppressants, as well as those with mental illness. 6. Pregnant or lactating women. 7. Patients with keloid-prone skin or keloids. 8. Patients who refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Physician’s Global Assessment;

Secondary

MeasureTime frame
VISIA absolute score;Noninvasive skin physiological index;

Countries

China

Contacts

Public ContactXiang Wen

West China Hospital, Sichuan University

xiangwen_wcums@163.com+86 189 8060 6449

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026